Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
TRVI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.30 - $7.39
Previous CloseN/A
Volume226.18K
Average Volume (3M)3.60M
Market Cap
$586.86M
Enterprise Value$330.17M
Total Cash (Recent Filing)$22.02M
Total Debt (Recent Filing)$5.29M
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
May 08, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding96,682,230
10 Day Avg. Volume1,540,946
30 Day Avg. Volume3,599,882
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.91
Forecast
1Y Price Target
$18.85Price Target Upside210.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Trevi Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe company recently announced positive data from their Phase 2a trial in refractory chronic cough (RCC).
Financial StabilityTrevi has a cash position of $107.6 million, providing financial stability to complete ongoing trials, though additional funds will be needed for future phases.
Regulatory And Market PositionUpcoming catalysts include major data releases from ongoing studies and key regulatory meetings, which could positively influence the company's future prospects.
Bears Say
Funding NeedsTrevi has a cash position of $107.6 million, providing financial stability to complete ongoing trials, though additional funds will be needed for future phases.
Market CompetitionManagement provided insights on competitor programs, enhancing understanding of Haduvio's position in the broader landscape of IPF and RCC.
Trial Discontinuation ConcernsManagement reaffirmed that blinded discontinuation rates in the CORAL trial have tracked in the single-digit percentage range, compared to mid-teens in previous studies.
---
Ownership Overview
12.20% Insiders
5.50% Mutual Funds
1.45% Other Institutional Investors
72.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $2.30 and its highest was $7.39 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $586.86M.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is May 08, 2025 which is in 14 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Mar 18, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.128 by $0.018.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 96,682,230 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.128. Following the earnings report the stock price went up 3.811%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
---
Trevi Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.85 (210.54% Upside)
$18.85 (210.54% Upside)
Blogger Sentiment
Bullish
TRVI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $51.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.46%
12-Months-Change
Fundamentals
Return on Equity
-52.59%
Trailing 12-Months
Asset Growth
24.04%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
---
TRVI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical successes and a strong financial position, but increased losses and expenses present challenges. Overall, the positive clinical outcomes suggest a promising outlook for the company despite the financial setbacks.Read More>---
TRVI Stock 12 Month Forecast
Average Price Target
$18.85
▲(210.54% Upside)
Technical Analysis
Prothena
―
Rocket Pharmaceuticals
―
AnaptysBio
―
Dianthus Therapeutics
―
Pharming Group
―
Best Analysts Covering TRVI
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+71.68%
reiterated a buy rating last month
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +71.68% per trade.
---